Dr. Rangasamy Ramanathan of Los Angeles
General Medical Center will present published data showing EHMD
adoption saved $1.8M over two years
by reducing length of stay and parenteral nutrition use
DUARTE,
Calif., May 3, 2024 /PRNewswire/ -- Prolacta
Bioscience, the world's leading hospital provider of 100% human
milk-based nutritional products for critically ill, premature
infants, announced today that Dr. Rangasamy
Ramanathan, professor of pediatrics division chief, division
of neonatal medicine, Los Angeles General Medical Center and PIH
Good Samaritan Hospital, will present published data on the
financial and clinical benefits of implementing an Exclusive Human
Milk Diet (EHMD) for very low birth weight (VLBW) infants during
the 2024 Pediatric Academic Societies (PAS) Meeting on Saturday, May 4, 6:30-8
p.m. ET, in Toronto.
PAS connects thousands of leading pediatric researchers,
clinicians, and medical educators worldwide to advance scientific
discovery and promote innovation in child and adolescent
health.
Dr. Ramanathan's presentation will summarize data published in
the peer-reviewed journal Breastfeeding Medicine. The
symposium, titled "Exclusive Human Milk-Based Nutrition: A
Cost-Effective Way to Decrease Morbidities in Preterm Infants,"
highlights real-world cost-benefit analysis data from a Level III
county neonatal intensive care unit (NICU) showing:
- Adoption of Prolacta's EHMD in VLBW infants generated a
$1.8 million cost savings (or
$31.8K per infant) over two years by
reducing mean length of stay by 6.3 days per infant and mean
parenteral nutrition (PN) use by 6.8 days per infant,
respectively.1
- Combining the cost avoidance from improved clinical outcomes,
the estimated financial impact over two years excluding insurance
reimbursement was an estimated $913,840 ($16,032
per infant).1
"Our study demonstrates that implementing an EHMD can be a
cost-effective approach in improving health outcomes for preterm
infants," said Dr. Ramanathan. "We saw significant reductions in
length of stay and days on parenteral nutrition, which directly
translated to substantial cost savings for our NICU."
"This real-world experience at a safety-net hospital adds to the
growing evidence that an EHMD is not only best for premature
infants but can also be a financially prudent decision for neonatal
care providers," stated Melinda
Elliott, MD, FAAP, practicing neonatologist and chief
medical officer for Prolacta. "We encourage PAS attendees to attend
the symposium to learn more about the clinical and financial
benefits of EHMD implementation."
Register here to attend the symposium, including a panel
discussion with Jonathan Swanson,
MD, and Jenelle Ferry, MD, moderated
by Erin Hamilton Spence, MD,
director of clinical education and professional development for
Prolacta.
Real-World Evidence Demonstrates Improved Outcomes and
Reduced Costs
Extensive real-world data affirm EHMD adoption
enables critical health improvements for premature infants and
major cost reductions for hospitals. Analysis of 2019-2022 data
from 3,000+ patients at 60+ U.S. hospitals found EHMD
implementation improved health outcomes and reduced costs,
generating a 2.6X dollar-for-dollar return on
investment.2 Similarly, a 2023 peer-reviewed report
found EHMD implementation resulted in a 3X dollar-for-dollar return
on investment from a reduction in comorbidities and shorter lengths
of stay among very low birth weight infants.3
The body of real-world evidence in support of human milk-based
fortifiers (HMBF) is substantial. It has been clinically proven in
more than 20 peer-reviewed clinical studies that compared to bovine
milk-based fortifiers (BMBF), HMBF when used as part of an EHMD
demonstrated:
- Lower mortality and morbidity4-6
- Reduced incidence of feeding intolerance7
- Achieved adequate growth8-10
- Reduced incidence of bronchopulmonary dysplasia
(BPD)4,7,8,11
- Reduced incidence of retinopathy of prematurity
(ROP)4,11,12
- Reduced late-onset sepsis incidence and
evaluations4,11,12
- Reduced risk of necrotizing enterocolitis
(NEC)4,7,13
- Improved long-term outcomes such as
neurodevelopment14,15
- Shortened stays in the NICU7
- Reduced hospital costs1,3,7,16,17
- Achieved better growth in term infants recovering from surgery
for single ventricle physiology (SVP)18
About Prolacta Bioscience
Prolacta Bioscience® is a
global life sciences company dedicated to Advancing the Science of
Human Milk® to improve health outcomes for critically ill and
premature infants. More than 100,000 extremely premature
infants19 worldwide have benefited from Prolacta's human
milk-based products, which have been evaluated in more than 20
peer-reviewed clinical studies. Hospitals adopting Prolacta's
Exclusive Human Milk Diet realize up to a 3X return on
investment.3 Operating the world's first
pharmaceutical-grade human milk processing
facilities, Prolacta maintains the industry's strictest
quality and safety standards, with over 20 validated tests for
screening and testing human milk. Prolacta's manufacturing process
uses vat pasteurization to ensure pathogen inactivation while
protecting nutritional composition and bioactivity. Learn more at
www.prolacta.com, on X, Instagram, Facebook, and LinkedIn.
Media Contact:
Loren
Kosmont
Lkosmont@prolacta.com
310-721-9444
References
- Tetarbe M, Chang MR, Barton L, Cayabyab R, Ramanathan R.
Economic and clinical impact of using human milk-derived fortifier
in very low birth weight infants. Breastfeed Med. 2024
Feb;19(2):114-119. doi: 10.1089/bfm.2023.0163 Epub 2024 Jan 30.
PMID: 38294868.
- Data on file; hospital-provided outcomes analysis from 2019 to
2022.
- Swanson JR, Becker A, Fox J, et al. Implementing an exclusive
human milk diet for preterm infants: real-world experience in
diverse NICUs. BMC Pediatr. 2023;23(1).
doi.org/10.1186/s12887-023-04047-5
- Hair AB, Peluso AM, Hawthorne KM, et al. Beyond necrotizing
enterocolitis prevention: improving outcomes with an exclusive
human milk-based diet [published correction appears in
Breastfeed Med. 2017 Dec;12 (10):663]. Breastfeed
Med. 2016;11(2):70-74. doi:10.1089/bfm.2015.0134
- Abrams SA, Schanler RJ, Lee ML, Rechtman DJ. Greater
mortality and morbidity in extremely preterm infants fed a diet
containing cow milk protein products. Breastfeed Med.
2014;9(6):281-285. doi:10.1089/bfm.2014.0024
- Cristofalo EA, Schanler RJ, Blanco CL, et al.
Randomized trial of exclusive human milk versus preterm formula
diets in extremely premature infants. J Pediatr.
2013;163(6):1592-1595.e1. doi:10.1016/j.jpeds.2013.07.011
- Assad M, Elliott MJ, Abraham JH. Decreased cost and improved
feeding tolerance in VLBW infants fed an exclusive human milk diet.
J Perinatol. 2016;36(3):216-220.
doi:10.1038/jp.2015.168
- Huston R, Lee M, Rider E, et al. Early fortification of enteral
feedings for infants <1250 grams birth weight receiving a human
milk diet including human milk-based fortifier. J Neonatal
Perinatal Med. 2020;13(2):215-221.
doi:10.3233/NPM-190300
- Huston RK, Markell AM, McCulley EA, Gardiner SK, Sweeney SL.
Improving growth for infants ≤1250 grams receiving an exclusive
human milk diet. Nutr Clin Pract.
2018;33(5):671-678. doi:10.1002/ncp.10054
- Hair AB, Hawthorne KM, Chetta KE, Abrams SA. Human milk feeding
supports adequate growth in infants ≤ 1250 grams birth weight.
BMC Res Notes. 2013;6:459. Published 2013 Nov 13.
doi:10.1186/1756-0500-6-459
- Delaney Manthe E, Perks PH, Swanson JR. Team-based
implementation of an exclusive human milk diet. Adv Neonatal
Care. 2019;19(6):460-467. doi:10.1097/ANC.0000000000000676
- O'Connor DL, Kiss A, Tomlinson C, et al. Nutrient enrichment of
human milk with human and bovine milk-based fortifiers for infants
born weighing <1250 g: a randomized clinical trial [published
correction appears in Am J Clin Nutr. 2019
Aug 1;110(2):529] [published
correction appears in Am J Clin Nutr. 2020
May 1;111(5):1112]. Am J Clin
Nutr. 2018;108(1):108-116. doi:10.1093/ajcn/nqy067
- Sullivan S, Schanler RJ, Kim JH, et al. An exclusively
human milk-based diet is associated with a lower rate of
necrotizing enterocolitis than a diet of human milk and bovine
milk-based products. J Pediatr. 2010;156(4):562-7.e1.
doi:10.1016/j.jpeds.2009.10.040
- Bergner EM, Shypailo R, Visuthranukul C, et al.
Growth, body composition, and neurodevelopmental outcomes at 2
years among preterm infants fed an exclusive human milk diet in the
neonatal intensive care unit: a pilot study. Breastfeed Med.
2020. 15(5):304-311. doi:10.1089/bfm.2019.0210
- Rahman A, Kase J, Murray Y, et al. Neurodevelopmental outcome
of extremely low birth weight infants fed an exclusive human milk
diet is not affected by growth velocity. Breastfeed Med.
2020;15(6):362-369. doi:10.1089/bfm.2019.0214
- Ganapathy V, Hay JW, Kim JH. Costs of necrotizing enterocolitis
and cost-effectiveness of exclusively human milk-based products in
feeding extremely premature infants. Breastfeed Med.
2012;7(1):29-37. doi:10.1089/bfm.2011.0002
- Data on file; hospital-provided outcomes analysis from 2019 to
2022.
- Blanco CL, Hair A, Justice LB, Roddy D, Bonagurio K, Williams
PK, Machado D, Marino BS, Chi A, Takao C, Gordon EE, Ashrafi A,
Cacho N, Pruetz JD, Costello JM, Cooper DS, & Cardiac
Neonate Nutrition Study Group. A randomized trial of an exclusive
human milk diet in neonates with single ventricle physiology.
J Pediatr. 2022;256: 105–112.
doi.org/10.1016/j.jpeds.2022.11.043
- Data on file; estimated number of infants fed Prolacta's
products from January 2007 to
August 2023.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pediatric-academic-societies-meeting-includes-symposium-on-cost-effectiveness-of-implementing-exclusive-human-milk-based-nutrition-for-premature-infants-302135387.html
SOURCE Prolacta Bioscience